You are here: Industry Insights > TIGIT

News List

Another Giant Entering, the TIGIT Antibody Market is Highly Competitive PharmaSources/Dopine
July 09, 2021
GlaxoSmithKline (GSK) and iteos Therapeutics have announced a collaboration to jointly develop and commercialize EOS-448. EOS-448 is an anti-TIGIT monoclonal antibody, which is in the phase I development.
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI321 (Anti-PD-1/TIGIT Bispecific Antibody) in Patients with Advanced Malignant Tumors prnasia
July 26, 2021
Innovent Biologics, Inc. today announced that the first patient has been dosed in a Phase 1 study of IBI321, an anti-PD-1/TIGIT bispecific antibody.
iTeos Therapeutics, GSK Enter Monoclonal Antibody Alliance contractpharma
June 15, 2021
GSK now has a leading portfolio of antibodies targeting the CD226 axis, a key target for next-gen immuno-oncology therapies.
Agenus and BMS Announce License for Anti-TIGIT Bispecific Antibody Program americanpharmaceuticalreview
May 19, 2021
Bristol-Myers Squibb Company and Agenus Inc. have entered into a definitive agreement under which Bristol Myers Squibb will be granted a global exclusive license to Agenus’ proprietary bispecific antibody program, AGEN1777, that blocks TIGIT and a ...
Compugen Announces Triple Combination Study to Evaluate COM701, Opdivo, TIGIT Inhibitor americanpharmaceuticalreview
March 09, 2020
Compugen announced its plan to initiate a Phase 1/2 study evaluating a triple combination of Compugen's COM701, an investigational anti-PVRIG antibody ...